Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
This is a single arm, multi-institution (1) Hackensack Meridian Health at Hackensack, New Jersey (NJ) (2) Jersey Shore Medical Center, Neptune, NJ and (3) Georgetown/Lombardi Cancer Center) phase II study of the combination of pembrolizumab, belantamab, and dexamethasone in patients with triple class refractory multiple myeloma.
Multiple Myeloma, Refractory
DRUG: Pembrolizumab|DRUG: Belantamab mafodotin|DRUG: Dexamethasone
Overall Response Rate (ORR), To evaluate the overall response rate for pembrolizumab, belantamab and dexamethasone (PBd) in patients with triple class refractory multiple myeloma., 2 years
Progression-Free Survival (PFS), To assess rates of progression-free survival (PFS), 2 years|Overall Survival (OS), To assess rates of overall survival (OS), 2 years|Time to next treatment, To assess rates of time to next treatment, 2 years|Tolerability and Safety, To determine the tolerability and safety of the combination of pembrolizumab with belantamab and dexamethasone by rate of incidence of adverse events using National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE), v5.0, 2 years
This is a single arm, multi-institution (1) Hackensack Meridian Health at Hackensack, NJ (2) Jersey Shore Medical Center, Neptune, NJ and (3) Georgetown/Lombardi Cancer Center) phase II study of the combination of pembrolizumab, belantamab, and dexamethasone in patients with triple class refractory multiple myeloma. All institutions will share the same Institutional Review Board.

Safety lead-in Cohort: After the first 10 patients are enrolled, an independent safety review committee will meet to review adverse events and toxicity and determine whether the trial will continue to enroll.

Phase 2 portion: The remainder of patients will be enrolled using a Simon's - 2 stage design.

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.